Cargando…

eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma

BACKGROUND: Immune checkpoint blockade (ICB) targeting programmed death ligand-1 (PD-L1)/programmed cell death protein-1 (PD-1) pathway has become an attractive strategy for cancer treatment; however, unsatisfactory efficacy has limited its clinical benefits. Therefore, a more comprehensive understa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xisha, Wang, Kuansong, Jiang, Shilong, Sun, Hongyin, Che, Xuanling, Zhang, Minghui, He, Jiaying, Wen, Ying, Liao, Mengting, Li, Xiangling, Zhou, Xiaoming, Song, Jianxun, Ren, Xingcong, Yi, Wenjun, Yang, Jinming, Chen, Xiang, Yin, Mingzhu, Cheng, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961175/ https://www.ncbi.nlm.nih.gov/pubmed/35347072 http://dx.doi.org/10.1136/jitc-2021-004026

Ejemplares similares

Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy
por: Guan, Yidi, et al.
Publicado: (2020)

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy
por: Sun, Guangshun, et al.
Publicado: (2022)

Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers
por: Li, Jinming, et al.
Publicado: (2023)

Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
por: Sui, Qiaoqi, et al.
Publicado: (2021)

Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study
por: Huang, Weicai, et al.
Publicado: (2023)

Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities
por: Lin, Jian, et al.
Publicado: (2022)

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen
por: Chen, Pu, et al.
Publicado: (2023)

ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer
por: Wang, Zongren, et al.
Publicado: (2021)

Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS
por: Zhang, Man, et al.
Publicado: (2023)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
por: Zhang, Libin, et al.
Publicado: (2021)

Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer
por: Mao, Misha, et al.
Publicado: (2022)

Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
por: Sun, Xiaoyan, et al.
Publicado: (2022)

Tobacco exposure primes the secretion of CCL21 positively associated with tertiary lymphoid structure and response to immunotherapy
por: Yin, Xuewen, et al.
Publicado: (2023)

ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer
por: Chen, Huanhuan, et al.
Publicado: (2023)

Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases
por: Zhang, Chong, et al.
Publicado: (2023)

Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8(+) T cell infiltration and functional transition
por: Yu, Anze, et al.
Publicado: (2023)

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
por: Merino, Diana M, et al.
Publicado: (2020)

KALRN mutations promote antitumor immunity and immunotherapy response in cancer
por: Li, Mengyuan, et al.
Publicado: (2020)

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2020)

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma
por: Yang, Lei, et al.
Publicado: (2022)

Siglec-9(+) tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer
por: Wang, Yiying, et al.
Publicado: (2023)

Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
por: Chen, Xiaofeng, et al.
Publicado: (2021)

Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma
por: Yao, Yao, et al.
Publicado: (2020)

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
por: Xiao, Gang, et al.
Publicado: (2023)

Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology
por: Wang, Ya-Qin, et al.
Publicado: (2020)

Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy
por: Shi, Lin, et al.
Publicado: (2023)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
por: He, Bingxi, et al.
Publicado: (2020)

Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation
por: Wen, Lei, et al.
Publicado: (2022)

Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy
por: Shi, Jiawei, et al.
Publicado: (2022)

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma
por: Wang, Yuelong, et al.
Publicado: (2020)

Targeting KDM4C enhances CD8(+) T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer
por: Jie, Xiaohua, et al.
Publicado: (2022)

Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers
por: Ying, Jieer, et al.
Publicado: (2021)

Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade
por: He, Meng, et al.
Publicado: (2023)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors
por: Chen, Di, et al.
Publicado: (2020)

Mitochondrial Lon-induced mtDNA leakage contributes to PD-L1–mediated immunoescape via STING-IFN signaling and extracellular vesicles
por: Cheng, An Ning, et al.
Publicado: (2020)

Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma
por: Ma, Yuxiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l61or6qg6ljdt3hs7hv71v3b6g